HUE044465T2 - Kalcitonin mimetikumok betegségek és rendellenességek kezelésére - Google Patents

Kalcitonin mimetikumok betegségek és rendellenességek kezelésére

Info

Publication number
HUE044465T2
HUE044465T2 HUE17208140A HUE044465T2 HU E044465 T2 HUE044465 T2 HU E044465T2 HU E17208140 A HUE17208140 A HU E17208140A HU E044465 T2 HUE044465 T2 HU E044465T2
Authority
HU
Hungary
Prior art keywords
disorders
treating diseases
calcitonin mimetics
calcitonin
mimetics
Prior art date
Application number
Other languages
English (en)
Inventor
Morten Karsdal
Kim Henriksen
Kim Vietz Andreassen
Original Assignee
Keybioscience Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201320112A external-priority patent/GB201320112D0/en
Priority claimed from GB201414706A external-priority patent/GB201414706D0/en
Application filed by Keybioscience Ag filed Critical Keybioscience Ag
Publication of HUE044465T2 publication Critical patent/HUE044465T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
HUE17208140 2013-11-14 2014-11-10 Kalcitonin mimetikumok betegségek és rendellenességek kezelésére HUE044465T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201320112A GB201320112D0 (en) 2013-11-14 2013-11-14 Calcitonin Mimetics for treating diseases and disorders
GB201414706A GB201414706D0 (en) 2014-08-19 2014-08-19 Calcitonin mimetics for treating diseases and disorders

Publications (1)

Publication Number Publication Date
HUE044465T2 true HUE044465T2 (hu) 2019-10-28

Family

ID=51947308

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE17208140 HUE044465T2 (hu) 2013-11-14 2014-11-10 Kalcitonin mimetikumok betegségek és rendellenességek kezelésére
HUE14802345A HUE037663T2 (hu) 2013-11-14 2014-11-10 Kalcitonin mimetikumok betegségek és rendellenességek kezelésére

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE14802345A HUE037663T2 (hu) 2013-11-14 2014-11-10 Kalcitonin mimetikumok betegségek és rendellenességek kezelésére

Country Status (24)

Country Link
US (2) US10232021B2 (hu)
EP (3) EP3321278B1 (hu)
JP (1) JP6639389B2 (hu)
KR (1) KR20160075794A (hu)
CN (1) CN105722854B (hu)
AU (2) AU2014350328B2 (hu)
BR (1) BR112016010643A2 (hu)
CA (1) CA2928654A1 (hu)
CY (2) CY1119976T1 (hu)
DK (2) DK3068796T3 (hu)
ES (2) ES2713851T3 (hu)
HR (2) HRP20180337T1 (hu)
HU (2) HUE044465T2 (hu)
LT (2) LT3321278T (hu)
MX (1) MX2016006049A (hu)
NO (1) NO3068796T3 (hu)
PH (1) PH12016500705B1 (hu)
PL (2) PL3068796T3 (hu)
PT (2) PT3321278T (hu)
RS (2) RS57152B1 (hu)
RU (1) RU2689551C1 (hu)
SI (2) SI3068796T1 (hu)
TR (1) TR201802765T4 (hu)
WO (1) WO2015071229A1 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201500263D0 (en) * 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
KR101869595B1 (ko) 2016-06-08 2018-06-21 부경대학교 산학협력단 성게 유래 칼시토닌 유사 펩타이드를 유효성분으로 포함하는 골 질환 예방 또는 치료용 조성물
CN108424460A (zh) * 2017-02-13 2018-08-21 成都贝爱特生物科技有限公司 GLP-1类似物和davalintide类似物的融合蛋白制备及其用途
CN106880835A (zh) * 2017-02-17 2017-06-23 云南同方科技有限公司 用于缓解高血压症状的植物精油复合物制备及应用
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
CA3156452A1 (en) 2019-11-11 2021-05-20 Boehringer Ingelheim International Gmbh NPY2 RECEPTOR AGONISTS
KR20230045088A (ko) 2020-08-07 2023-04-04 베링거 인겔하임 인터내셔날 게엠베하 가용성 npy2 수용체 작용제
AR124295A1 (es) 2020-12-18 2023-03-15 Lilly Co Eli Agonistas duales del receptor de amilina y calcitonina y usos de los mismos
WO2024050289A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions for oral delivery

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
JPH03240797A (ja) * 1990-02-15 1991-10-28 Sagami Chem Res Center 新規カルシトニン誘導体
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
JPH04149198A (ja) * 1990-10-12 1992-05-22 Sagami Chem Res Center カルシトニン誘導体
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2285658C (en) 1997-04-16 2011-10-04 Nozar M. Mehta Direct expression of peptides into culture media
DE19736457C2 (de) * 1997-08-21 2001-08-23 Fraunhofer Ges Forschung Calcitonin-Derivate mit einer Verbrückung zwischen den Aminosäuren an den Positionen 17 und 21
EP1137431A1 (en) 1998-12-04 2001-10-04 Provalis UK Limited Pharmaceutical compositions containing insulin
CA2369591C (en) 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
JP2006521366A (ja) 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド シームレスマイクロカプセルを含む固形経口剤形
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
CA2532565C (en) 2003-07-23 2012-05-08 Novartis Ag Use of calcitonin in osteoarthritis
EP1670500A2 (en) 2003-09-17 2006-06-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
EP1768676A1 (de) 2004-07-22 2007-04-04 ThioMatrix Forschungs- und Beratungs GmbH Verwendung von thiolgruppen-haltigen verbindungen als efflux-pumpen-hemmer
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
EP1907561B1 (en) 2005-06-24 2013-08-28 Unigene Laboratories, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
EP2722054B1 (en) 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
ATE515260T1 (de) 2006-03-13 2011-07-15 Advanced In Vitro Cell Technologies S L Stabile nanokapselsysteme für die verabreichung von wirkstoffen
MX2008012678A (es) 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
CN106971232B (zh) * 2011-10-25 2021-01-26 Nicira股份有限公司 网络控制系统中的控制器
CA2854175A1 (en) 2011-11-02 2013-05-10 Keybioscience Ag Peptide analogs for treating diseases and disorders

Also Published As

Publication number Publication date
NO3068796T3 (hu) 2018-06-30
US10232021B2 (en) 2019-03-19
JP2016538282A (ja) 2016-12-08
RS57152B1 (sr) 2018-07-31
TR201802765T4 (tr) 2018-03-21
LT3068796T (lt) 2018-05-10
CN105722854B (zh) 2020-08-04
PT3321278T (pt) 2019-03-19
EP3068796A1 (en) 2016-09-21
SI3068796T1 (en) 2018-05-31
EP3068796B1 (en) 2018-01-31
CA2928654A1 (en) 2015-05-21
MX2016006049A (es) 2016-08-12
PT3068796T (pt) 2018-03-02
US20170143800A1 (en) 2017-05-25
CY1121332T1 (el) 2020-05-29
PH12016500705A1 (en) 2016-05-30
LT3321278T (lt) 2019-03-12
RU2689551C1 (ru) 2019-05-28
ES2660788T3 (es) 2018-03-26
SI3321278T1 (sl) 2019-04-30
CN105722854A (zh) 2016-06-29
US20190142903A1 (en) 2019-05-16
HRP20180337T1 (hr) 2018-05-18
HUE037663T2 (hu) 2018-09-28
PL3068796T3 (pl) 2018-07-31
AU2018202480A1 (en) 2018-04-26
EP3470422A1 (en) 2019-04-17
CY1119976T1 (el) 2018-12-12
EP3321278B1 (en) 2019-01-09
KR20160075794A (ko) 2016-06-29
HRP20190356T1 (hr) 2019-04-19
PL3321278T3 (pl) 2019-06-28
JP6639389B2 (ja) 2020-02-05
RU2016123180A (ru) 2017-12-19
EP3321278A1 (en) 2018-05-16
AU2014350328A1 (en) 2016-05-19
RS58530B1 (sr) 2019-04-30
ES2713851T3 (es) 2019-05-24
DK3321278T3 (en) 2019-03-25
WO2015071229A1 (en) 2015-05-21
DK3068796T3 (en) 2018-03-05
BR112016010643A2 (pt) 2017-12-05
PH12016500705B1 (en) 2016-05-30
AU2014350328B2 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
HRP20190356T1 (hr) Mimetici kalcitonina za liječenje bolesti i poremećaja
IL273688A (en) Evaluation and treatment of bradykinin-mediated disorders
HK1224182A1 (zh) 用於治療神經疾病的包含托拉塞米和巴氯芬的組合物
HK1221408A1 (zh) 用於治療成膠質細胞瘤的組合療法
PL3046470T3 (pl) Diagnozowanie i leczenie zaburzeń ruchu
ZA201607581B (en) Dosage forms and therapeutic uses l-4lchlorokynurenine
IL253026A0 (en) Calcitonin analogs for the treatment of diseases and disorders
IL276431A (en) Treatment of the brain disorders and related symptoms
HUE039105T2 (hu) Kalcitonin mimetikumok betegségek és rendellenességek kezelésére
GB201320112D0 (en) Calcitonin Mimetics for treating diseases and disorders
GB201414706D0 (en) Calcitonin mimetics for treating diseases and disorders
GB201313178D0 (en) Therapeutic treatments
GB201313182D0 (en) Therapeutic treatments